Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 7, 2026, 6:37 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2665–2688 of 50,397 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Cancer Clear all

Conditions: Pancreatic Cancer
Interventions: physiologic testing; Other
Lead sponsor: Case Comprehensive Cancer Center; Other
Eligibility: Not listed
Enrollment: 9 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2009
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Breast Cancer
Interventions: Paclitaxel, Eribulin, 5-Fluorouracil, Epirubicin, Cyclophosphamide, Doxorubicin; Drug
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older · Female only
Enrollment: 54 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2020
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Advanced Solid Cancers, Metastatic Cancer
Interventions: Cdc7-inhibitor; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years and older
Enrollment: 11 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 3
States / cities: Boston, Massachusetts • Detroit, Michigan

Conditions: Cervical Cancer
Interventions: da Vinci, open surgery; Device · Other
Lead sponsor: GOG Foundation; Network
Eligibility: 18 Years and older · Female only
Enrollment: 840 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2030
U.S. locations: 133
States / cities: Goodyear, Arizona • Duarte, California • Encinitas, California + 87 more

Conditions: Breast Cancer
Interventions: environmental intervention; Other
Lead sponsor: University of Washington; Other
Eligibility: 18 Years and older · Female only
Enrollment: 211 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2016
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Carcinoid Cancer, Neuroendocrine Tumors, Medullary Thyroid Cancer, Cancers Expressing Somatostatin Receptors
Interventions: 68Ga DOTATATE; Drug
Lead sponsor: Jonsson Comprehensive Cancer Center; Other
Eligibility: 18 Years and older
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Solid Tumors, Brain Tumors, Brain Metastases
Interventions: Satraplatin; Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 3 Years to 25 Years
Enrollment: 9 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2015
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Colon Cancer
Interventions: Perifosine, Capecitabine, Perifosine Placebo; Drug · Other
Lead sponsor: AEterna Zentaris; Industry
Eligibility: 18 Years and older
Enrollment: 381 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2011
U.S. locations: 49
States / cities: Tucson, Arizona • Beverly Hills, California • Deer Park, California + 45 more

Conditions: Pancreatic Cancer, Benign Pancreatic Disease
Interventions: Not listed
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 181 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2027
U.S. locations: 1
States / cities: New York, New York

Conditions: Breast Cancer
Interventions: exemestane, tamoxifen, triptorelin; Drug
Lead sponsor: ETOP IBCSG Partners Foundation; Network
Eligibility: 18 Years to 65 Years · Female only
Enrollment: 2,672 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2024
U.S. locations: 139
States / cities: Burbank, California • La Jolla, California • Mission Hills, California + 106 more

Conditions: Prostate Cancer
Interventions: risedronate, Placebo risedronate oral tablet; Drug
Lead sponsor: UConn Health; Other
Eligibility: 55 Years to 85 Years · Male only
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2009
U.S. locations: 1
States / cities: Farmington, Connecticut

Conditions: Breast Cancer, Leptomeningeal Disease
Interventions: cDC1 Vaccine, Trastuzumab, Nivolumab; Biological · Drug
Lead sponsor: H. Lee Moffitt Cancer Center and Research Institute; Other
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2030
U.S. locations: 1
States / cities: Tampa, Florida

Conditions: Breast Cancer
Interventions: GDC-0810, LHRH Agonist, Palbociclib; Drug
Lead sponsor: Genentech, Inc.; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 152 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2020
U.S. locations: 8
States / cities: San Diego, California • Boston, Massachusetts • St Louis, Missouri + 3 more

Conditions: Esophageal Squamous Cell Carcinoma, High Grade Serous Ovarian Cancer, Head and Neck Squamous Cell Carcinoma, Colorectal Cancer, Castration-resistant Prostate Cancer, Non Small Cell Lung Cancer, Endometrium Cancer, Triple Negative Breast Cancer
Interventions: IDE034; Drug
Lead sponsor: IDEAYA Biosciences; Industry
Eligibility: 18 Years and older
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 15
States / cities: Denver, Colorado • Sarasota, Florida • Detroit, Michigan + 10 more

Conditions: Lung Cancer, Metastatic Cancer
Interventions: Cryotherapy (PTC), Prednisone; Procedure · Drug
Lead sponsor: Barbara Ann Karmanos Cancer Institute; Other
Eligibility: 18 Years to 120 Years
Enrollment: 9 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2021
U.S. locations: 1
States / cities: Detroit, Michigan

Conditions: Breast Cancer
Interventions: Anastrozole; Drug
Lead sponsor: Roxane Laboratories; Industry
Eligibility: 18 Years to 45 Years
Enrollment: 32 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2006
U.S. locations: 1
States / cities: Springfield, Missouri

Conditions: Non Small Cell Lung Cancer
Interventions: Heart Rate Variability Biofeedback Training; Behavioral
Lead sponsor: Abramson Cancer Center at Penn Medicine; Other
Eligibility: 18 Years to 70 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Lymphoma
Interventions: Carfilzomib; Drug
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2017
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Graft Versus Host Disease, Hematologic Neoplasms
Interventions: Busulfan, Fludarabine, Cyclophosphamide, Mycophenolate Mofetil, Sirolimus; Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 12 Years to 120 Years
Enrollment: 105 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2026
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Pediatric Cancer
Interventions: Patient population; Other
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: Not listed
Enrollment: 60 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2026
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Breast Cancer
Interventions: Doxorubicin / Cyclophosphamide / Paclitaxel / Carboplatin, Definitive Surgery, Radiotherapy; Drug · Procedure · Radiation
Lead sponsor: Leo W. Jenkins Cancer Center; Other
Eligibility: 18 Years to 75 Years · Female only
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2016
U.S. locations: 1
States / cities: Greenville, North Carolina

Conditions: Barrett's Esophagus, Gastroesophageal Reflux Disease
Interventions: Not listed
Lead sponsor: Midwest Biomedical Research; Other
Eligibility: 18 Years and older
Enrollment: 89 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2017
U.S. locations: 1
States / cities: Kansas City, Missouri

Conditions: Leukemia
Interventions: Immunotoxin therapy, CAT-8015 immunotoxin, Biological therapy; Drug · Procedure
Lead sponsor: Cambridge Antibody Technology; Other
Eligibility: 18 Years and older
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2007
U.S. locations: 3
States / cities: Beverly Hills, California • Indianapolis, Indiana • Bethesda, Maryland

Conditions: Renal Cell Carcinoma
Interventions: Arterial Spin Labeling Magnetic Resonance Imaging; Other
Lead sponsor: Beth Israel Deaconess Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 32 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2019
U.S. locations: 2
States / cities: Boston, Massachusetts

Search by objective public record fields.

Changes in Muscle Tissue in Patients With Pancreatic Cancer

Neoadjuvant Study of Sequential Eribulin Followed by FAC Compared to Sequential Paclitaxel Followed by FEC in Early Stage Breast Cancer Not Overexpressing HER-2

A Study of BMS-863233 in Patients With Advanced and/or Metastatic Solid Tumors

A Trial of Robotic Versus Open Hysterectomy Surgery in Cervix Cancer

Healthy Families to Change Obesity in Public Housing Residents

68Ga DOTATATE PET/CT in Neuroendocrine Tumors (Expanded Access)

Satraplatin in Children and Young Adults With Refractory Solid Tumors Including Brain Tumors

Placebo-Controlled Study of Perifosine + Single Agent Chemotherapy for Metastatic Cancer Patients

Interrogation of Exosome-mediated Intercellular Signaling in Patients With Pancreatic Cancer

Triptorelin With Either Exemestane or Tamoxifen in Treating Premenopausal Women With Hormone-Responsive Breast Cancer

Effect Of Risedronate On Bone Mass In Older Men Receiving Neoadjuvant Therapy For Prostate Cancer

Trial of Therapies With IT cDC1s Combined w/ IT Trastuzamab for Her+ or IT Nivolumab for Her- BC LMD

A Study of GDC-0810 Single Agent or in Combination With Palbociclib and/or a Luteinizing Hormone-Releasing Hormone (LHRH) Agonist in Women With Locally Advanced or Metastatic Estrogen Receptor Positive Breast Cancer

A Study of IDE034 in Adult Participants With Locally Advanced/Metastatic Solid Tumors Types

Cryotherapy in Treating Patients With Primary Stage I Non-Small Cell Lung Cancer or Lung Metastasis

Bioequivalency Study of Anastrozole 1 mg Under Fed Conditions

Lung Heart Rate Variability

A Phase II Study of Carfilzomib in the Treatment of Relapsed/Refractory Mantle Cell Lymphoma

Optimizing PTCy Dose and Timing

Barriers and Facilitators in Access to OT/PT in Pediatric Cancer Survivors

Phase II Trial of Neoadjuvant Metronomic Chemotherapy in Triple-Negative Breast Cancer

Quality of Life in Barrett's Esophagus and Gastro-Esophageal Reflux Disease

Safety Study of CAT-8015 Immunotoxin in Patients With CLL, PLL or SLL With Advance Disease

Arterial Spin Labeling Blood Flow MRI for Evaluation of Response to Antiangiogenic and Targeted Therapies of Renal Cell Carcinoma (RCC)